178 related articles for article (PubMed ID: 17542771)
1. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.
Vourvahis M; Kashuba AD
Pharmacotherapy; 2007 Jun; 27(6):888-909. PubMed ID: 17542771
[TBL] [Abstract][Full Text] [Related]
2. Tipranavir: a novel nonpeptidic protease inhibitor of HIV.
King JR; Acosta EP
Clin Pharmacokinet; 2006; 45(7):665-82. PubMed ID: 16802849
[TBL] [Abstract][Full Text] [Related]
3. Tipranavir: a new option for the treatment of drug-resistant HIV infection.
Temesgen Z; Feinberg J
Clin Infect Dis; 2007 Sep; 45(6):761-9. PubMed ID: 17712762
[TBL] [Abstract][Full Text] [Related]
4. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.
Dumond JB; Vourvahis M; Rezk NL; Patterson KB; Tien HC; White N; Jennings SH; Choi SO; Li J; Wagner MJ; La-Beck NM; Drulak M; Sabo JP; Castles MA; Macgregor TR; Kashuba AD
Clin Pharmacol Ther; 2010 Jun; 87(6):735-42. PubMed ID: 20147896
[TBL] [Abstract][Full Text] [Related]
5. Drug interactions of tipranavir, a new HIV protease inhibitor.
Morello J; Rodriguez-Novoa S; Jimenez-Nacher I; Soriano V
Drug Metab Lett; 2007 Jan; 1(1):81-4. PubMed ID: 19356024
[TBL] [Abstract][Full Text] [Related]
6. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
Arribas JR
Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
[TBL] [Abstract][Full Text] [Related]
8. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
[TBL] [Abstract][Full Text] [Related]
9. Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies.
Boffito M; Maitland D; Pozniak A
J Clin Pharmacol; 2006 Feb; 46(2):130-9. PubMed ID: 16432264
[TBL] [Abstract][Full Text] [Related]
10. Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: implications for tipranavir use.
Gallego O; de Mendoza C; Corral A; Barrios A; Soriano V
AIDS Patient Care STDS; 2005 Feb; 19(2):67-9. PubMed ID: 15716637
[No Abstract] [Full Text] [Related]
11. Tipranavir: PNU 140690, tipranivir.
Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
[TBL] [Abstract][Full Text] [Related]
12. Tipranavir: a novel second-generation nonpeptidic protease inhibitor.
Kandula VR; Khanlou H; Farthing C
Expert Rev Anti Infect Ther; 2005 Feb; 3(1):9-21. PubMed ID: 15757454
[TBL] [Abstract][Full Text] [Related]
13. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.
González de Requena D; Calcagno A; Bonora S; Ladetto L; D'Avolio A; Sciandra M; Siccardi M; Bargiacchi O; Sinicco A; Di Perri G
AIDS; 2006 Oct; 20(15):1977-9. PubMed ID: 16988521
[TBL] [Abstract][Full Text] [Related]
14. Tipranavir: a review of its use in the management of HIV infection.
Orman JS; Perry CM
Drugs; 2008; 68(10):1435-63. PubMed ID: 18578560
[TBL] [Abstract][Full Text] [Related]
15. Tipranavir: a protease inhibitor for HIV salvage therapy.
Dong BJ; Cocohoba JM
Ann Pharmacother; 2006; 40(7-8):1311-21. PubMed ID: 16788094
[TBL] [Abstract][Full Text] [Related]
16. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.
Kakuda TN; Schöller-Gyüre M; Hoetelmans RM
Antivir Ther; 2010; 15(6):817-29. PubMed ID: 20834094
[TBL] [Abstract][Full Text] [Related]
17. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
[TBL] [Abstract][Full Text] [Related]
18. Induction effects of ritonavir: implications for drug interactions.
Foisy MM; Yakiwchuk EM; Hughes CA
Ann Pharmacother; 2008 Jul; 42(7):1048-59. PubMed ID: 18577765
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.
MacGregor TR; Sabo JP; Norris SH; Johnson P; Galitz L; McCallister S
HIV Clin Trials; 2004; 5(6):371-82. PubMed ID: 15682350
[TBL] [Abstract][Full Text] [Related]
20. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
Luna B; Townsend MU
Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]